Summary
The pharmacokinetics of omeprazole and its metabolites were studied in 8 healthy elderly volunteers using [14C]omeprazole. In another 6 healthy elderly volunteers, the pharmacokinetics of omeprazole were studied using unlabelled drug. Each volunteer received single doses of omeprazole intravenously (20mg) and orally (40mg) as solutions in a randomised crossover design. The plasma concentrations and urinary excretion of omeprazole and metabolites were followed for 24 and 96h, respectively.
The results indicate that the average metabolic capacity of omeprazole is decreased in the elderly compared with that found in earlier studies of healthy young individuals. This was reflected in an increase in bioavailability from 56 to 76%, a reduction in mean systemic clearance by approximately 50% (0.25 L/min) and a prolongation of the mean elimination half-life from 0.7 to 1.0h compared with the young.
Despite these findings, the considerable overlap in these parameters between young and old volunteers, together with data from previous pharmacodynamic studies and the wide therapeutic range of omeprazole, indicate that dosage reductions are not needed in the elderly.
Similar content being viewed by others
References
Andersson T, Cederberg C, Regårdh CG, Skånberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. European Journal of Clinical Pharmacology 39: 195–197, 1990a
Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Therapeutic Drug Monitoring 12: 415–416, 1990b
Andersson T, Olsson R, Regårdh CG, Skånberg I. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clinical Pharmacokinetics, in press, 1993
Bardhan KD, Bianchi Porro G, Bose K, Daly M, Hinchliffe RFC, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. Journal of Clinical Gastroenterology 8: 408–413, 1986
Brändström A, Lindberg P, Bergman NÅ, Alminger T, Ankner K, et al. Chemical reactions of omeprazole and omeprazole analogues. Acta Chemica Scandinavica 43: 536–611, 1989
Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+, K+)ATPase. Nature 290: 159–161, 1981
Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. New England Journal of Medicine 306: 1081–1088, 1982
Grundevik I, Jerndal G, Balmér K, Persson BA. Fully automated gradient elution liquid Chromatographic assay of omeprazole and 2 metabolites. Journal of Pharmacology and Biomedical Analysis 4: 389–398, 1986
Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903–912, 1988
Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, Meuwissen SGM, Lamers CBHW. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1: 349–351, 1987
Lamy P. Modifying drug dosage in elderly patients. In Covington & Walker (Eds) Current Geriatric Therapy, pp. 35–72, Saunders Company, Philadelphia, 1984
Larsson M, Jagenburg R, Landahl S. Renal function in an elderly population. A study of S-creatinine, 51Cr-EDTA clearance, endogenous creatinine clearance and maximal tubular water reabsorption. Scandinavian Journal of Clinical and Laboratory Investigation 46: 593–598, 1986
Lind T, Andersson T, Skånberg I, Olbe L. Biliary excretion of intravenous [14C)omeprazole in humans. Clinical Pharmacology and Therapeutics 42: 504–508, 1987
Lind T, Cederberg C, Axelson M, Olbe L. Long-term acid inhibitory effect of different daily doses of omeprazole 24 hours after dosing. Scandinavian Journal of Gastroenterology 21 (Suppl. 118): 137–138, 1986
Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin stimulated acid secretion in man. Gut 24: 270–276, 1983
Lind T, Cederberg C, Olausson M, Olbe L. Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin. European Journal of Clinical Pharmacology 40: 557–560, 1991
Loo JCK, Riegelman S. Assessments of pharmacokinetic constants from post infusion blood curve obtained after iv infusion. Journal of Pharmaceutical Sciences 59: 53–57, 1970
Lorentzon P, Eklundh B, Brändström A, Wallmark B. The mechanism for inhibition of gastric (H++K+)-ATPase by omeprazole. Biochimica et Biophysica Acta 817: 25–32, 1985
Naesdal J, Andersson T, Bodemar G, Larsson R, Regårdh CG, et al. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clinical Pharmacology and Therapeutics 40: 344–351, 1986
Regårdh CG, Andersson T, Lagerström PO, Lundborg P, SkÅnberg I. The pharmacokinetics of omeprazole in humans — a study of single intravenous and oral doses. Therapeutic Drug Monitoring 12: 163–172, 1990
Regårdh CG, Gabrielsson M, Hoffman KJ, Löfberg I, Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man — an overview. Scandinavian Journal of Gastroenterology 20 (Suppl. 108): 79–94, 1985)
Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. Journal of Pharmacokinetics and Biopharmaceutics 13: 185–201, 1985
Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clinical Pharmacology and Therapeutics 48: 365–374, 1990
Vestal RE. Drug use in the elderly: a review of problems and special considerations. Drugs 16: 358–382, 1978
Vestal RE. Aging and determinants of hepatic drug clearance. Hepatology 9: 331–334, 1989
Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. New England Journal of Medicine 320: 69–75, 1989
Wallmark B, Lorentzon P, Larsson H. The mechanism of action of omeprazole — a survey of its inhibitory actions in vitro. Scandinavian Journal of Gastroenterology 20 (Suppl. 108): 37–51, 1985
Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9: 297–301, 1989
Wynne HA, Goudevenos J, Rawlins MD, James OFW, Adams PC, et al. Hepatic drug clearance: the effect of age using indocyanine green as a model compound. British Journal of Clinical Pharmacology 30: 634–637, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Landahl, S., Andersson, T., Larsson, M. et al. Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers. Clin. Pharmacokinet. 23, 469–476 (1992). https://doi.org/10.2165/00003088-199223060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199223060-00006